The Immune System’s Peacekeepers

How this year’s Nobel Prize winners found the body’s hidden regulators and opened the door to breakthroughs in autoimmune diseases

When the immune system works properly, it performs an extraordinary balancing act. It must be aggressive enough to destroy dangerous pathogens and cancerous cells yet restrained enough to avoid turning against the body’s own healthy tissues. For decades, scientists suspected that specialized cells must exist to maintain this delicate equilibrium, but they remained undiscovered. This year’s Nobel Prize in Physiology or Medicine recognizes three researchers who finally revealed these elusive peacekeepers of the immune system—and in doing so, opened pathways toward treating millions of people living with autoimmune diseases.

The Nobel committee awarded Mary Brunkow of the Institute for Systems Biology in Seattle, Fred Ramsdell of Sonoma Biotherapeutics, and Shimon Sakaguchi of the University of Osaka the prize for their groundbreaking discoveries concerning peripheral immune tolerance. Their work unveiled a previously unknown class of immune cells, known as regulatory T cells, which act as the body’s internal brake system, preventing immune responses from spiraling out of control.

A decades-long mystery solved

The story begins in 1995, when Sakaguchi and his team at the University of Osaka identified a rare and specialized subtype of white blood cell. These cells, which they termed regulatory T cells, comprise only 1 to 2 percent of all T cells circulating in the body. Despite their scarcity, they wield enormous influence over immune function.

The discovery was revelatory because it provided the first concrete evidence for a regulatory mechanism that immunologists had long theorized must exist. Without such a system, the immune system would be like a car without brakes—relentless, dangerous, and uncontrollable.

Sakaguchi’s experiments with mice first demonstrated just how crucial these cells are. When regulatory T cells (Tregs) were removed from laboratory animals, the mice rapidly developed severe autoimmune conditions affecting multiple organs, including the thyroid and pancreas. Even more remarkably, when researchers administered regulatory T cells back to these sick animals, disease progression halted. This elegant demonstration proved that Tregs weren’t just passive bystanders but active suppressors of autoimmune reactions.

Regulatory T cells may be vastly outnumbered by other, more abundant T cell counterparts, but they’re highly specialized for their role. Much like a detachment of elite special forces, they can have profound effects in small numbers. When inflammation begins to escalate at a site of immune activity, these cells migrate to the location and effectively shut down the response, preventing collateral damage to healthy tissue while still allowing the immune system to do its essential work of fighting genuine threats.

Unlocking the molecular machinery

The next breakthrough came in 2001, when Brunkow and Ramsdell made a crucial discovery. Working independently, they identified mutations in a gene called Foxp3 that caused fatal autoimmune disease in mice. The research represented a painstaking molecular investigation, tracking down a tiny genetic alteration that produced profound consequences throughout the immune system.

The implications extended beyond rodents. Brunkow and Ramsdell demonstrated that mutations in the human version of Foxp3 caused a rare but devastating genetic autoimmune disorder called IPEX. This finding established a direct link between the gene and autoimmune disease, as well as implicating Treg as key drivers in humans.

Two years later, Sakaguchi and his colleagues connected the final pieces of the puzzle. Their follow-up studies revealed that Foxp3 is significantly expressed in Tregs and is essential for both their development and function. The gene acts as a master switch, determining whether a developing T cell will become an immune aggressor or a regulator. The discovery provided scientists with a reliable molecular marker to identify regulatory T cells, enabling them to isolate and study these cells systematically for the first time.

Transforming our understanding of autoimmunity

The identification of regulatory T cells and their genetic blueprint fundamentally changed how scientists think about autoimmune diseases. Rather than viewing these conditions solely as the result of overactive immune cells attacking the body, researchers could now frame them as a failure of regulation—a breakdown in the system meant to keep out-of-control immune responses in check.

Approximately one in ten people worldwide suffers from autoimmune conditions, such as type 1 diabetes, rheumatoid arthritis, and lupus. Subsequent work has revealed that many individuals with these disorders have either an insufficient number of regulatory T cells in their bloodstream or cells that do not function properly. This deficiency leaves the immune system without adequate regulatory control, allowing inflammatory responses to damage healthy tissues.

The key discoveries by Sakaguchi, Ramsdell, and Brunkow also reshaped research into other areas of medicine. Scientists now recognize that regulatory T cells play important roles in preventing transplant rejection, controlling chronic inflammatory conditions, and even influencing cancer progression. Some tumors exploit these cells to suppress anti-cancer immune responses, while in other contexts, boosting regulatory T cell activity could prevent harmful inflammation.

From laboratory discovery to medical treatments

Perhaps the most exciting aspect of this Nobel-prize Prize-winning work is its translation into potential therapies. More than 200 clinical trials are currently underway testing regulatory T cell-based treatments for conditions ranging from type 1 diabetes and motor neuron disease to transplant rejection and rare skin disorders.
Two main therapeutic approaches have emerged. The first involves extracting a patient’s own regulatory T cells, growing large numbers of them in laboratory culture, and then infusing them back into the patient—a personalized cellular therapy that could help restore immune balance. The second approach uses drugs to stimulate the body’s natural production of these regulatory cells, potentially offering a less invasive treatment option.

However, significant challenges remain. Regulatory T cells are notoriously difficult to work with—they are rare, fragile, and must be carefully maintained outside of a patient’s body to preserve their suppressive function. Researchers are working to overcome these obstacles through improved cell culture strategies, better understanding of how these cells develop and function, and innovative approaches to delivering them to the right locations in the body by harnessing synthetic CAR molecules.

A foundation for future medicine

The work recognized by this year’s Nobel Prize exemplifies how fundamental biological discoveries can transform the field of medicine. When Sakaguchi, Ramsdell, and Brunkow first identified regulatory T cells and their molecular underpinnings, they could not have predicted the explosion of research and therapeutic development that would follow. 

For the estimated 800 million people worldwide living with autoimmune conditions, the recognition of this foundational work brings hope. The peacekeepers of the immune system, once unknown, are now at the centre of an ambitious effort to restore balance to unwanted immune responses—a fitting legacy for discoveries that have fundamentally changed our understanding of how the body protects itself from both external and internal threats.